Trial Profile
Five Versus Three Years of Adjuvant Imatinib in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor: A Phase III, Randomized, Multicenter Study (FAITH study)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 21 Mar 2018
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Acronyms FAITH study
- 21 Mar 2018 New trial record